Active Biotech Ab · OMXSTO:ACTI
Active Biotech Ab — Investor Presentation (March 2024)
29 slides from Active Biotech Ab's investor presentation, March 2024
Slide 1: Active Biotech
Slide 2: Disclaimer
Disclaimer • Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or i
Slide 3: Active Biotech in Brief
Active Biotech in Brief Clear focus on specialist disease areas Finance & Corporate • Large unmet medical need and value potential • Listed on Nasdaq Stockholm (ticker: ACTI) • Hematological cancers (clinical Ph I/IIa study ongoing) • Market cap SEK 240 M, USD 22,6 M* • Inflammatory eye disorders (c
Slide 4: Immunomodulation to Treat Cancer and Inflammation
Immunomodulation to Treat Cancer and Inflammation Small molecules Antibody based immunotherapy - myeloid cell modulation - tumor targeting superantigen Tasquinimod Naptumomab Superantigen-dependent cellular cytotoxicity Laquinimod Abbrev:, MDSC – Myeloid derived suppressor cell; HDAC4 – Histone deac
Slide 5: Valuable Clinical Pipeline in Specialist Indications
Valuable Clinical Pipeline in Specialist Indications LAQUINIMOD 5
Slide 6: Key Collaborations with Academic Partners
Key Collaborations with Academic Partners Tasquinimod Multiple myeloma • Yulia Nefedova, M.D., Ph.D. Associate Professor, Immunology, Microenvironment & Metastasis Program, The Wistar Institute Cancer Center, Philadelphia, US • Kim De Veirman, PhD, Brussels Health Campus VUB, Brussels Myelofibrosis
Slide 7: Tasquinimod: New Type of Treatment for Hematological Malignances with Unmet Medical Need
Tasquinimod: New Type of Treatment for Hematological Malignances with Unmet Medical Need Ongoing study Core focus High value opportunity Multiple myeloma (MM) Myelofibrosis (MF) Myelodysplastic syndrome (MDS) Blocking of the tumor-supportive bone Disease modifying by targeting the Restoration of hem
Slide 8: Multiple Myeloma: An Incurable Blood Cancer
Multiple Myeloma: An Incurable Blood Cancer • Multiple myeloma develops in the bone marrow • Uncontrollable growth of plasma cells • Formation of new blood cells prevented • Leads to bone pain, fractures, anemia and other severe complications, e g renal failure and infections • Survival has increase
Slide 9: Tasquinimod: Synergy in Combination with Anti-Myeloma Treatments
Tasquinimod: Synergy in Combination with Anti- Myeloma Treatments Tasquinimod in combination with Tasquinimod in combination with proteasome inhibitors (PIs) an immunomodulatory drug (IMiD) Vehicle Vehicle Vehicle tasq 400 400 Tumor Area (mm2) tasq 300 ixa len Tumor Area (mm2) tasq tasq + len Tumor
Slide 10: Ongoing Ph Ib/IIa Study in Multiple Myeloma
Ongoing Ph Ib/IIa Study in Multiple Myeloma Patients Patients Primary endpoint MM relapsed or refractory after ≥1 line of anti-MM therapy and refractory or MM relapsed or refractory after Safety & tolerability, intolerant to lenalidomide, pomalidomide, bortezomib, carfilzomib, and an anti- ≥1 line o
Slide 11: Multiple Myeloma: Market Driven by Novel Treatments
Multiple Myeloma: Market Driven by Novel Treatments ~880,000 people Total patients treated → Duplet → Triplet → Quadruplet → Quintuplet multiple myeloma drug combination regimens ~215,000 people Treated in 2 line ~295,000 Treated in 3+ lines Eight major markets: $22bn in sales in people 2027 Commerc
Slide 12: Myelofibrosis: Rare Blood Cancer
Myelofibrosis: Rare Blood Cancer Myelofibrosis (MF) – In brief Tasquinimod Ameliorates Hallmarks of MF in a Mouse model • A rare blood cancer with an annual incidence of 0.4 - 1.3 cases per 100 000 people in Europe • Market estimated to above USD 2.9 billion* • Abnormal production of blood-forming c
Slide 13: Combination with Tasquinimod and a BET inhibitor or a JAK inhibitor is Effective in a Mouse Model of MF
Combination with Tasquinimod and a BET inhibitor or a JAK inhibitor is Effective in a Mouse Model of MF* Reduced spleen length Reduced spleen size Increased survival ✱✱ 40 Vehicle ✱✱✱ 10 weeks of treatment Spleen length (in mm) ✱ ✱ 100 30 mg/kg Tasquinimod 30 ✱✱✱✱ 30 mg/kg ruxolitinib ✱✱✱✱ ✱ ✱ 75 %
Slide 14: Tasquinimod: Development in Myelofibrosis
Tasquinimod: Development in Myelofibrosis • Global patent license agreement between Active Biotech and Oncode Institute/Erasmus MC since Feb 2022 • Clinical PoC with tasquinimod alone in Europe, to start in 2024 • Study funded by Oncode Institute • To be conducted by HOVON in the Netherlands and Ger
Slide 15: Myelofibrosis: Need for Disease Modifying Treatment
Myelofibrosis: Need for Disease Modyfing Treatment 85,000 people Total prevalent cases for myelofibrosis (primary and secondary MF) • Major unmet medical need • Only one drug class approved 67,200 people Total treated patients Commercial potential: USD 750 million /year Eight major markets: USD 2.9
Slide 16: Laquinimod: Novel Treatment for Eye Disorders
Laquinimod: Novel Treatment for Eye Disorders Core focus High value indications Non-infectious uveitis Eye disorders with excessive neovascularization Laquinimod induces immune tolerance by Laquinimod reduces the pro-inflammatory targeting antigen presenting cells and angiogenic response by targetin
Slide 17: Non-Infectious Uveitis: High Medical Need
Non-Infectious Uveitis: High Medical Need • Standard treatments Laquinimod • Corticosteroids: local and systemic • Immunosuppressants • Monoclonal antibodies • High medical need for new therapy to improve efficacy and limit side effects • As a steroid-sparing regimen Current treatment of non-infecti
Slide 18: Laquinimod Works Both Topically and Orally
Laquinimod Works Both Topically and Orally Topical laquinimod Oral laquinimod Inhibition of Histological ocular evaluation Topical endoscopic fundus imaging (TEFI) experimental uveitis by ✱✱✱ laquinimod is associated ✱✱✱ Posterior histological scores 30 with: Posterior clinical scores 6 Vehicle (ora
Slide 19: Laquinimod Development Program in Eye Disorders
Laquinimod Development Program in Eye Disorders • Innovative gel like eye drop formulation*, developed, optimized and manufactured • Available IND regulatory package complemented with required pre-clinical eye toxicity & tolerance studies • Safety and tolerability confirmed in clinical Phase I study
Slide 20: Safety and Tolerability Profile of Laquinimod Eye Drops Confirmed in Healthy Subjects
Safety and Tolerability Profile of Laquinimod Eye Drops Confirmed in Healthy Subjects Single-Ascending Dose Multiple Dose • Laquinimod or placebo • Laquinimod or placebo Subjects Dose-escalation based on Dose/Duration: (N=54) • Adverse events • Once daily for up to 21 days • Eye examinations Assessm
Slide 21: Laquinimod: Clinical Development in Uveitis
Laquinimod: Clinical Development in Uveitis ✓Generate data on safety and tolerability of laquinimod eye drops in healthy subjects • Safety and tolerability confirmed in completed phase I study • Confirm biodistribution in the eye after ocular administration to patients • Study to start in Q1 2024 at
Slide 22: Uveitis: Significant Opportunity
Uveitis: Significant Opportunity Significant opportunity in segment of non-infectious non-anterior uveitis in 9MM, forecasts for 2029 ~258,000 • Corticosteroids only effective in 60% people Total diagnosed • Clinical consequences serious prevalent cases ~205,000 people Total treated cases (1LoT: cor
Slide 23: Naptumomab: Tumor Directed Immunotherapy
Naptumomab: Tumor Directed Immunotherapy Combination with Combination with Combination with checkpoint inhibition chemo chemotherapy CART Cell Treatment Preclinical data suggest synergy Preclinical data suggest synergy Preclinical data suggest synergy with checkpoint inhibitors with chemotherapy wit
Slide 24: Naptumomab: Clinical Studies
Naptumomab: Clinical Studies • Phase IIa study of naptumomab + docetaxel in lung cancer Treatment and Endpoints (NCT04880863) Naptumomab + Docetaxel after Obinutuzumab • Patients (N=35): Progressive NSCLC, no prior docetaxel, prior exposure to pre-treatment checkpoint inhibitor • Status: Second stag
Slide 25: Safety and Preliminary Activity of Naptumomab Estafenatox and Durvalumab Interim Results
Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors Interim Results from a Phase Ib Trial Poster presentation at AACR 2023 • 59 patients with various advanced/metastatic solid tumors and a median of 3 prior lines • Recom
Slide 26: Projected Clinical Milestones Through 2024
Projected Clinical Milestones Through 2024 Tasquinimod • Ph Ib/IIa combination with IRd in multiple myeloma: Final results H2 2024 • Ph II Myelofibrosis • Start of study in Europe, Q3 2024 • Start of study in US, H1 2024 Laquinimod • Clinical biodistribution study of eye drop • Start of study, Q1 20
Slide 27: Financials For the Period January – December, 2023
Financials For the Period January – December, 2023 • Operating expenses January – December, 2023 MSEK 46,5 (57,9) a 24% reduction reflecting reduced clinical and CMC costs. • Rights issue concluded in Q4, 2023 added 41,8 MSEK to liquidity after issue costs • Available cash at Dec. 31, 2023 - MSEK 36
Slide 28: Management
Management Helén Tuvesson Hans Kolam Erik Vahtola President & CEO CFO CMO Born 1962. CEO since 2017. Born 1951. CFO since 2000. Born 1976. CMO since 2022. Education: MSc, PhD in cell and molecular Education: B.Sc in Business Administration Education: Medical Doctor (MD) and PhD in biology in medical
Slide 29: www.activebiotech.com
Acti ¢ Biotech /) www.activebiotech.com 29